Mizuho reiterates Corvus Pharmaceuticals stock rating on pipeline

Investing.com · 2026-11-06 16:08 UTC

Mizuho reiterates Corvus Pharmaceuticals stock rating on pipeline

Investing.com - Mizuho reiterated an Outperform rating and $27.00 price target on Corvus Pharmaceuticals (NASDAQ:CRVS) following the company’s third-quarter results. The stock currently trades at $10.27, suggesting significant upside potential to the analyst target, with Wall Street maintaining a Strong Buy consensus rating.

The firm highlighted updated timelines across multiple programs for the company’s lead asset soquelitinib, an oral ITK inhibitor being developed for oncology and autoimmune conditions.

Corvus Pharmaceuticals has as many as five clinical data-related catalysts expected over the next year. The company’s cash runway extends to the second quarter of 2028, supported by a robust current ratio of 16.16 and a balance sheet that holds more cash than debt.

Read the full story at Investing.com · All coverage of this story